Multiply Labs raised $75 million to scale robotic drug manufacturing toward commercial-scale workflows. The company focuses on automating midstream logistics between existing cell therapy manufacturing instruments, including moving bags, taking samples, and transferring material. The investment highlights how cell therapy manufacturers are seeking throughput and cost reductions that can translate into access. Multiply Labs claims large improvements in cost per dose and throughput, aiming to connect robotic “task” automation into full, reliable end-to-end protocols. In parallel, broader bioprocess modeling efforts are gaining momentum, with work on hybrid digital twins and multi-fidelity training approaches meant to improve prediction while reducing reliance on expensive high-fidelity process data. For the sector, these developments signal that industrialization—not just discovery—is becoming a core competitive battleground in biotech.